Biopharma Dealmakers Face Policy Uncertainty as MFN Drug Pricing Rules Shift the US Market

Introduction

2026 is a turbulent year for biopharma, as US drug pricing becomes more directly shaped by policy than ever before. The Trump administration’s Most Favored Nation (MFN) pricing strategy has inserted a new layer of uncertainty and complexity into dealmaking and commercial strategy. As global and domestic players gather for events such as the BIO International Convention, one major topic has come front and center: How can biopharma companies safeguard 'premium pricing' as new legislative and administrative frameworks take hold?

This report explores the evolving tactics of biotech and pharma dealmakers, the practical implications of regulatory change, and the rapidly shifting calculus of US market access in light of ongoing drug pricing reform.

What Is the MFN Rule—and Why Does It Matter?

The MFN policy—In simple terms, the US government now seeks to peg reimbursement rates for prescription drugs to prices paid in other developed countries, instead of allowing pharmaceutical firms to set prices largely unrestrained. The ostensible rationale: US consumers should not systematically pay more for drugs than their counterparts abroad. However, the knock-on effects for the pharmaceutical value chain, investment strategies, and innovation incentives are extensive.

Dealmakers across the biopharma industry are contending with immense operational ambiguity. While the rule aims to address longstanding affordability issues, its implementation carries ripple effects for negotiating power, pricing leverage, and share valuation across biotech and pharma companies.

How Business Development Is Changing

From Price Certainty to Policy Risk

Business development teams have traditionally structured deals—including licensing, co-development, and mergers—based on stability and high predictability of US drug pricing, especially for specialty therapies and new launches. With MFN provisions in place, the old risk calculations around 'premium pricing'—charging more for drugs in the US versus international markets—are fundamentally upended.

Today’s deals must consider:

• Policy Uncertainty: There is no guarantee that current MFN policies will remain in place, be rescinded, or revised by future administrations, creating a volatile backdrop.
• Renegotiation Clauses: New contracts increasingly include flexible provisions to adjust pricing or payment terms in response to regulatory changes. This level of conditionality was much less common a decade ago.
• Risk Management: Collaboration, partnerships, and value-based agreements designed to share or mitigate pricing risk are growing. Innovative structures, such as milestone payments that adjust with policy changes, are emerging.

The Larger Market Impact

By integrating policy risk into every transaction, business development and commercial teams are being forced to collaborate more closely with regulatory, legal, and government affairs counterparts. Even large pharma companies known for sophisticated legal teams are now modeling multiple 'what-if' scenarios to prepare for regulatory upheaval.

Across the industry, the ability to remain agile in negotiation, while justifying the presumed value of innovative drugs, takes on new urgency. MFN rules also create the potential for more disputes during and after contract execution, as stakeholders seek to ensure their financial models remain robust despite regulatory intervention.

The Strategic Response: Practical Tactics in a New Normal

Renegotiation and Flexibility

Contemporary licensing and collaboration agreements now often feature clauses allowing for renegotiation if there are substantial regulatory shifts. This means that should reimbursement mechanisms or reference countries change, both parties may have the option to address the new circumstances, share financial impacts, or even terminate agreements.

Geographic Diversification

Companies are hedging risks by investing more in ex-US markets or seeking to diversify portfolios to reduce overreliance on the US pricing environment. Expansion into emerging markets and greater focus on global strategic partnerships have become pivotal.

Innovation Versus Access

There is ongoing debate about whether MFN-style policies will diminish innovation by making ROI less attractive or will simply force companies to focus on drugs with truly differentiated value. Investors must now factor in not just scientific merit and commercial potential, but also cross-border pricing harmonization and the likelihood of further regulatory disruption.

Policy Uncertainty as a Constant

While the Trump MFN rule is a clear inflection point, it’s worth noting that US health policy has been shifting for years. The presence of renegotiation clauses in biotech partnering is a symptom of a system where future reimbursement pathways are no longer reliably predictable. Political cycles, judicial reviews, and rapid changes in public sentiment all play a role.

The new reality is that no contract is immune from the reach of government reform—dealmakers must anticipate and build in contingencies for possible second- and third-order effects of policy shifts.

Implications for Key Stakeholders

Biotech Startups and Small Companies

For smaller firms, the stakes are high. The prospect of receiving lower reimbursements—and uncertainty over who bears the resulting shortfalls—may reduce the attractiveness of early out-licensing to larger partners or force startups to hold products for longer, broadening their capital requirements and diluting near-term returns.

Large Pharma

For established players, MFN policies increase diligence and contract complexity. Many are revamping their policy monitoring teams and seeking more stable, long-term alliances vs. one-off deals. Some may also accelerate investment in technologies that prove cost effectiveness, support real-world evidence generation, or bolster value-based contracting.

Investors and Payers

Investors in biotech and pharma—whether venture, private equity, or public market participants—are demanding new sensitivity analyses on regulatory maneuvers. Payers, meanwhile, are gaining more leverage in pricing negotiations but face their own uncertainties regarding supply, availability, and manufacturer willingness to prioritize the US market.

The Global Perspective: Policy Shocks Reverberate Abroad

One unintended consequence: international markets are now on alert. Countries referenced in US price benchmarking may see knock-on hikes in their own pharma costs, or, conversely, drug launch sequencing may shift to protect US premiums. The dialogue around pricing is thus more globalized than ever, with biopharma companies constantly recalibrating which markets to prioritize and when.

Looking Ahead

The only true certainty for biopharma dealmaking in 2026 is that uncertainty itself is here to stay. As MFN and related reforms embed policy risk deep into the heart of US market entry and global commercial strategies, the most agile and well-prepared organizations will have the upper hand.

The evolving state of drug pricing will push both small and large biopharma companies to rethink not just contracts and negotiations, but entire commercialization roadmaps.

Conclusion

Trump’s MFN drug pricing policy represents a seismic shift in how value is assessed, extracted, and protected in the US pharmaceutical market. For now, dealmakers must focus on designing resilient, flexible contracts that can weather regulatory storms and remain acutely aware of the ever-present risk that policy can—and will—reshape the business and innovation landscape.

Source: BioSpace